Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback